NGS Mini Lung Cancer Panel [20 DNA] Test: Booking, Price, and Results
About NGS Mini Lung Cancer Panel [20 DNA] Test: Booking, Price, and Results
| Field | Value |
|---|---|
| Also Known As | NGS Lung Cancer Panel, Lung Cancer Gene Panel, Lung Cancer Molecular Profiling Panel, Targeted NGS Panel for Lung Cancer |
| Sample Type | Tumour tissue (FFPE block from biopsy) |
| Fasting Required | No fasting required |
| Report Time | 16 days |
| Recommended For | Adults diagnosed with lung cancer, particularly non-small cell lung cancer (NSCLC), regardless of gender |
| Price | Starting at ₹14,400 |
What Is an NGS Mini Lung Cancer Panel [20 DNA] Test?
The NGS Mini Lung Cancer Panel [20 DNA] test is an advanced molecular test that analyses tumour tissue for genetic mutations across 20 cancer-related genes. It uses next-generation sequencing (NGS), a technology that reads large amounts of DNA simultaneously, to identify changes that may guide treatment decisions. Doctors typically order this test after a lung cancer diagnosis to understand the genetic profile of the tumour. It is also known as the Lung Cancer Molecular Profiling Panel or Targeted NGS Panel for Lung Cancer.
What Does an NGS Mini Lung Cancer Panel [20 DNA] Test Measure?
This panel examines 20 genes in tumour DNA to detect mutations such as single nucleotide variants, small insertions or deletions, gene fusions, and copy number changes. The genes included in this panel are listed below:
| Gene | What It Indicates |
|---|---|
| EGFR | Mutations that predict response to EGFR inhibitor drugs |
| KRAS | Common mutation in lung adenocarcinoma; some variants are now targetable |
| ALK | Gene rearrangements indicating eligibility for ALK inhibitor therapy |
| ROS1 | Gene fusions that respond to specific targeted therapies |
| BRAF | V600E mutation that may respond to BRAF and MEK inhibitor combinations |
| MET | Mutations and amplifications targetable with MET inhibitors |
| RET | Rearrangements that may be treated with RET inhibitors |
| ERBB2 (HER2) | Mutations indicating potential targeted therapy options |
| ERBB3 | Gene alterations associated with treatment response |
| ERBB4 | Gene alterations associated with treatment response |
| PIK3CA | Mutations that may affect treatment response |
| NRAS | Mutations relevant to tumour behaviour |
| AKT1 | Gene alteration relevant to cancer signalling pathways |
| MTOR | Mutations involved in cancer cell growth regulation |
| PDGFRA | Alterations relevant to targeted therapy eligibility |
| FGFR2 / FGFR3 | Gene alterations associated with tumour growth |
| RAF1 | Mutation associated with cancer cell signalling |
| SMO | Alteration relevant to specific cancer pathways |
| IDH1 / IDH2 | Metabolic gene mutations relevant to treatment planning |
The panel also includes JAK1, JAK2, JAK3, CDK4, KIT, CTNNB1, DDR2, MAP2K1, MAP2K2, GNA11, GNAQ, HRAS, ESR1, and FGFR2 among the 20 DNA targets tested.
Why Is an NGS Mini Lung Cancer Panel [20 DNA] Test Done?
This test is ordered when a doctor needs a detailed genetic profile of a lung tumour to guide the next steps in treatment planning.
Common Symptoms That May Require This Test
A lung cancer diagnosis, rather than symptoms alone, is the primary reason for ordering this panel. However, the following symptoms often lead to an initial workup:
- Persistent cough that does not improve over weeks
- Coughing up blood (haemoptysis)
- Unexplained weight loss
- Chest pain that worsens with breathing or coughing
- Shortness of breath (dyspnoea) during routine activity
- Recurrent respiratory infections such as pneumonia
Conditions This Test Can Help Detect
Once lung cancer is diagnosed, this panel helps characterise the tumour. It is used in the following situations:
- Non-small cell lung cancer (NSCLC), where targeted therapies depend on specific mutations
- Lung adenocarcinoma, a subtype that frequently carries actionable gene mutations
- Metastatic lung cancer that has spread beyond the lung
- Treatment-resistant cancers that have stopped responding to initial therapy
- Recurrent lung cancer that has returned after prior treatment
How to Prepare and What to Expect
This test requires tumour tissue collected during a biopsy. The preparation steps below apply to the patient and the referring clinician.
Do You Need to Fast?
No, fasting is not required for this test. The panel analyses DNA from tumour tissue, which is not affected by food or drink.
Practical Tips Before Your Test
The following tips will help ensure the test proceeds without delay:
- Bring a detailed clinical history, including your symptoms, previous test results, and any prior treatment records, as this is required for the test.
- Carry your histopathology examination (HPE) report and immunohistochemistry (IHC) report, if available.
- Inform your oncologist about all your current medications and supplements.
- Ensure the biopsy specimen has adequate tumour content, as the laboratory requires at least 20% tumour cells for a valid result.
- Confirm with your doctor that the tissue block has been properly fixed (10% neutral buffered formalin is the preferred fixation method).
Step-by-Step Procedure
The following steps describe how the sample is collected and processed for this test:
- A biopsy is performed by your surgeon or oncologist to collect tumour tissue. The sample is prepared as a formalin-fixed, paraffin-embedded (FFPE) tissue block.
- The FFPE tissue block is submitted to the Lupin Diagnostics laboratory along with your clinical history and relevant pathology reports.
- In the laboratory, DNA is extracted from the tumour tissue.
- The extracted DNA is prepared into a library of tagged fragments, which are then sequenced simultaneously using NGS technology.
- Specialised software analyses the sequencing data and compares the tumour DNA to a reference sequence to identify genetic alterations.
- A detailed report is prepared, listing any clinically relevant mutations detected, and delivered within the turnaround time.
Factors That Can Affect Accuracy
Several factors can influence the quality and reliability of results, including:
- Insufficient tumour cell content in the biopsy sample (below 20%)
- Poor tissue fixation or prolonged time between biopsy and fixation
- Degraded DNA due to improper sample storage or handling
- Tumour heterogeneity, where different regions of the tumour carry different mutations
- Mutations present at very low levels that fall below the detection threshold of the assay (approximately 5%)
Understanding Your NGS Mini Lung Cancer Panel [20 DNA] Test Results
Results from this panel should always be reviewed with a qualified oncologist who can interpret findings in the context of your overall health, disease stage, and treatment history.
| Result Category | What It Means |
|---|---|
| No pathogenic mutations detected | Wild-type result for all 20 genes; targeted therapy based on these markers may not apply |
| Mutation detected | A specific gene alteration is identified; your oncologist will assess whether a matched targeted therapy is available |
| Variant of uncertain significance (VUS) | A gene change is found but its clinical relevance is currently unclear |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
How to Maintain Healthy Levels
The following general wellness steps are relevant for anyone undergoing lung cancer evaluation:
- Maintain a smoke-free environment, as smoking exposure can drive additional mutations over time.
- Follow your oncologist's recommendations on treatment and follow-up scheduling.
- Discuss genetic counselling with your doctor if there is a family history of cancer, as some mutations may have hereditary implications.
Lupin Diagnostics NGS Mini Lung Cancer Panel [20 DNA] Test Price
The NGS Mini Lung Cancer Panel [20 DNA] test cost starts at ₹14,400 at Lupin Diagnostics. This test requires a visit to a Lupin Diagnostics centre or clinical facility; home collection is not available for this test.
| City | Approximate Price (₹) |
|---|---|
| BHOPAL | 14400 |
| CHENNAI | 14400 |
| HYDERABAD | 14400 |
| KOLKATA | 14400 |
| NAVI MUMBAI | 14400 |
| PUNE | 14400 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to book your NGS Mini Lung Cancer Panel [20 DNA] test online or through the Lupin Diagnostics website:
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample submission. Carry your FFPE tissue block and all relevant clinical documents.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
It is an advanced genetic test that uses next-generation sequencing to analyse 20 genes in tumour tissue. The aim is to identify specific mutations that can help an oncologist select the most appropriate targeted therapy for lung cancer.
This test is recommended for patients diagnosed with non-small cell lung cancer (NSCLC), lung adenocarcinoma, or metastatic lung cancer. It is also ordered when a tumour stops responding to treatment, or when cancer recurs after prior therapy.
The test requires a tumour tissue sample in the form of an FFPE (formalin-fixed, paraffin-embedded) tissue block, collected during a biopsy. The sample must have at least 20% tumour cell content. Clinical history and pathology reports must accompany the sample.
The NGS Mini Lung Cancer Panel [20 DNA] test has a report turnaround time of 16 days. This accounts for DNA extraction, sequencing, data analysis, and clinical reporting, all of which are steps that require careful processing.
A detected mutation means the tumour carries a specific genetic alteration. Your oncologist will assess whether a targeted therapy matched to that mutation is available, or whether eligibility for a clinical trial should be explored. Each mutation has different treatment implications.
No, home collection is not available for this test. The tumour tissue sample must be collected in a clinical or surgical setting by a qualified medical professional and transported to the laboratory under appropriate conditions.
NGS Mini Lung Cancer Panel [20 DNA] Test: Booking, Price, and Results
